INTRAINDIVIDUAL CROSS-OVER STUDY TO COMPARE MULTIHANCE AND OMNISCAN AT A DOSE OF 0.1 MMOL/KGBW IN THE DIFFERENTIAL DIAGNOSIS OF DISC HERNIATION VS. SCAR - ND

Start Date05 Jan 2009

Sponsor / Collaborator

Bracco Imaging Deutschland GmbH

EUCTR2006-002858-29-DE / Not yet recruitingNot Applicable

A DOUBLE-BLIND INTER-INDIVIDUAL COMPARISON OF IOMEPROL 300 AND IOMEPROL 400 IN THE ASSESSMENT OF PERFUSION CT OF ADVANCED RENAL CARCINOMA - Perfusion CT of Renal Carcinoma

Start Date27 Oct 2006

Sponsor / Collaborator

Bracco Imaging Deutschland GmbH

100 Clinical Results associated with Bracco Imaging Deutschland GmbH

0 Patents (Medical) associated with Bracco Imaging Deutschland GmbH

Literatures (Medical) associated with Bracco Imaging Deutschland GmbH

01 Jan 2014·Clinical Hemorheology and MicrocirculationQ4 · MEDICINE

Technical aspects of contrast-enhanced ultrasound (CEUS) examinations: Tips and tricks

Q4 · MEDICINE

Article

Author: Greis, C.

Ultrasound contrast agents have substantially extended the clinical value of ultrasound, allowing the assessment of blood flow and distribution in real-time down to microcapillary level. Selective imaging of contrast agent signals requires a contrast-specific imaging mode on the ultrasound scanner, allowing real-time separation of tissue and contrast agent signals. The creation of a contrast image requires a specific interaction between the insonated ultrasound wave and the contrast agent microbubbles, leading to persistent oscillation of the bubbles. Several technical and procedural parameters have a significant influence on the quality of CEUS images and should be controlled carefully to obtain good image quality and a reliable diagnosis. Achieving the proper balance between the respective parameters is a matter of technical knowledge and experience. Appropriate training and education should be mandatory for every investigator performing CEUS examinations.

01 Jun 2011·Der RadiologeQ4 · MEDICINE

Technische Grundlagen der Kontrastsonographie im Überblick und Ausblick in die Zukunft

Q4 · MEDICINE

Article

Author: Greis, C

Ultrasound contrast agents have considerably expanded the range of ultrasound diagnostics. Up to date ultrasound machines with contrast-specific software allow the selective demonstration and quantification of contrast agents in real-time based on the specific signal signature of oscillating contrast agent microbubbles. After intravenous injection the microbubbles are transported with the bloodstream and distributed purely intravascularly. This allows an artefact-free representation of the vascular architecture and delineation of the vascular lumen, independent of blood flow velocity and with high spatial resolution. Traumatic lesions and active bleeding can be detected with high sensitivity. Blood volume in vessels and organs can be assessed qualitatively and quantitatively. The possibility of short-term destruction of microbubbles within the ultrasound field allows the measurement of blood flow velocity during replenishment and based on that the assessment of perfusion in parenchymal tissue. Target-specific microbubbles for imaging of molecular surface structures as well as drug-loaded microbubbles for local ultrasound-mediated therapy are under development.

01 Jun 2006·American Journal of RoentgenologyQ2 · MEDICINE

Clinical Value of MDCT in the Diagnosis of Coronary Artery Disease in Patients with a Low Pretest Likelihood of Significant Disease

Q2 · MEDICINE

Article

Author: von Ziegler, Franz ; Wintersperger, Bernd J. ; Kirchin, Miles A. ; Reiser, Maximilian F. ; Nikolaou, Konstantin ; Knez, Andreas ; Rist, Carsten ; van Gessel, Roland ; Becker, Christoph R. ; Jakobs, Tobias F.

OBJECTIVEThe aim of this study was to evaluate the clinical value of MDCT in the diagnosis of coronary artery disease in a population having a low pretest likelihood of significant disease.SUBJECTS AND METHODSSixty-four patients with suspected coronary artery disease and a low pretest likelihood of significant disease according to the criteria of the American Heart Association underwent both MDCT of the heart and quantitative conventional coronary angiography (QCA). MDCT examinations were performed on a 16-MDCT scanner. CT data sets were evaluated on a per-patient basis and a per-segment basis and were classified as indicating no disease, nonsignificant disease (stenoses 50%). Sensitivity, specificity, negative predictive value (NPV), and positive predictive value (PPV) of 16-MDCT in the detection or exclusion of significant and nonsignificant coronary artery disease were evaluated on both per-patient and per-segment bases.RESULTSRegarding the success rate of 16-MDCT, 94% (60/64) of patients and 92% (388/420) of vessel segments were of sufficient quality for diagnosis. In the remaining 60 patients evaluated, QCA revealed significant coronary artery disease, nonsignificant disease, and no disease in 8.3% (5/60), 75.0% (45/60), and 16.7% (10/60) of cases, respectively, on a per-patient basis, and in 1.3% (5/388), 23.2% (90/388), and 75.5% (293/388) of cases, respectively, on a per-segment basis. The sensitivity, specificity, NPV, and PPV of 16-MDCT for the detection of significant coronary artery disease were 80.0%, 94.5%, 98.1%, and 57.1%, respectively, on a per-patient basis, and 80.0%, 99.2%, 99.7%, and 57.1% on a per-segment basis.CONCLUSIONIn a population having a low pretest likelihood of significant coronary artery disease, 16-MDCT shows a moderate to high sensitivity and high NPV for the detection or exclusion of significant disease, but has a somewhat reduced PPV compared with QCA.

100 Deals associated with Bracco Imaging Deutschland GmbH

100 Translational Medicine associated with Bracco Imaging Deutschland GmbH

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 25 Nov 2024

No data posted

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Bracco Imaging Deutschland GmbH

Overview

Related

Corporation Tree

Pipeline

Pipeline Snapshot as of 25 Nov 2024

Deal

Translational Medicine

Profit

Grant & Funding(NIH)

Investment

Financing